Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated label assessment claim elements (boxed warning malignancy risk/contraindication in current malignancy, and teratogenicity/fetal harm contraindications with contraception and pregnancy exclusion/testing) are fully supported by the provided FDA label excerpts, with no direct contradictions identified.
Category Scores
Accurate Statements
MAVENCLAD may increase the risk of malignancy.
BOXED WARNING (Malignancies): “may increase the risk of malignancy.”; Warnings 5.1 Malignancies: “may increase the risk of malignancy.”
MAVENCLAD is contraindicated in patients with current malignancy.
BOXED WARNING: “MAVENCLAD is contraindicated in patients with current malignancy.”; Contraindications (4): “in patients with current malignancy.”; Warnings 5.1.
In patients with prior malignancy or increased risk of malignancy, evaluate benefits and risks on an individual basis and follow standard cancer screening guidelines.
BOXED WARNING: “evaluate the benefits and risks… on an individual patient basis. Follow standard cancer screening guidelines…”; Warnings 5.1 repeats the same.
MAVENCLAD may cause fetal harm/teratogenicity and is contraindicated in pregnant women and in reproductive potential patients who do not plan to use effective contraception.
BOXED WARNING (Risk of Teratogenicity) and Contraindications (4): contraindicated in pregnant women and in females/males of reproductive potential who do not plan to use effective contraception because of potential fetal harm; Warnings 5.2.
Malformations and embryolethality occurred in animals.
BOXED WARNING (Risk of Teratogenicity): “Malformations and embryolethality occurred in animals.”; Warnings 5.2 and Use in Specific Populations (8.1) also state animal findings.
Exclude pregnancy prior to starting treatment in females of reproductive potential.
BOXED WARNING: “Exclude pregnancy before the start of treatment…”; Dosage and Administration 2.1: “Exclude pregnancy prior to treatment…”; Warnings 5.2 and Use in Specific Populations 8.3.
Advise/require effective contraception during MAVENCLAD dosing and for specified durations after the last dose in each treatment course (6 months for females, 14 weeks for males).
BOXED WARNING: “during MAVENCLAD dosing and for 6 months after the last dose… for females, and 14 weeks for males.”; Contraindications (4); Warnings 5.2; Use in Specific Populations 8.3.
Stop MAVENCLAD if the patient becomes pregnant.
BOXED WARNING: “Stop MAVENCLAD if the patient becomes pregnant.”
Unsupported Statements
Contradictions
Important Omissions
Specific label instruction to “After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years” (Warnings 5.1 / Dosage and Administration 2.2) is not included in the AI’s claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated AI content is a label-alignment assessment focusing on key boxed warning elements (malignancy risk and teratogenicity with contraception/pregnancy contraindications). It does not provide dosing instructions beyond contraception duration and does not contradict the label; the main omission is the post-2-course treatment interval restriction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing the label requirement not to administer additional MAVENCLAD for 2 years after completion of 2 treatment courses.
Suggested Improvement
Include the Warnings 5.1 / Dosage and Administration 2.2 statement: “After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years.”